Vanguard Group Inc. Has $80.43 Million Stock Position in Dynavax Technologies Corporation $DVAX

Vanguard Group Inc. lessened its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 3.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,099,758 shares of the biopharmaceutical company’s stock after selling 327,196 shares during the period. Vanguard Group Inc. owned 6.91% of Dynavax Technologies worth $80,431,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Hantz Financial Services Inc. boosted its position in shares of Dynavax Technologies by 236.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,710 shares in the last quarter. LSV Asset Management acquired a new position in Dynavax Technologies in the third quarter valued at approximately $89,000. Osaic Holdings Inc. lifted its stake in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares during the period. Summit Global Investments bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $113,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $121,000. 96.96% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO David F. Novack sold 114,000 shares of Dynavax Technologies stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the transaction, the chief operating officer owned 63,344 shares in the company, valued at $990,700.16. This trade represents a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.98% of the stock is owned by corporate insiders.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $15.50 on Friday. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $15.50 and a two-hundred day simple moving average of $12.26. Dynavax Technologies Corporation has a 1-year low of $9.20 and a 1-year high of $15.73. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -41.89 and a beta of 0.97.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DVAX. William Blair downgraded Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Dynavax Technologies to a “strong-buy” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $21.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.